Novartis follows Roche's Erivedge with hedgehog basal cell carcinoma success
This article was originally published in Scrip
Executive Summary
Novartis is to discuss with regulators the results of a Phase II study of its investigational oral product LDE225 (sonidegib) in advanced basal cell carcinoma after a significant tumor response rate was seen in the trial. The product, which acts on the hedgehog pathway, is already in Phase III trials for brain cancer (relapsed medulloblastoma).